Bryan, Garnier & Co acts as Joint Global Coordinator and Joint Bookrunner for Voluntis’ IPO, the first ever listing of a digital therapeutics company raising EUR 30.1 million

Bryan, Garnier & Co acts as Joint Global Coordinator and Joint Bookrunner for Voluntis’ IPO, the first ever listing of a digital therapeutics company raising EUR 30.1 million

News published on May Thursday 31, 2018
Share on

Context

Voluntis is a digital therapeutics pioneer that empowers people suffering from chronic conditions to self-manage their treatment every day, thus improving real-world outcomes.

A portfolio of solutions targeting the world’s top two therapy areas: diabetes and cancer.

Partnerships with leading players in their respective fields: Sanofi, AstraZeneca, Roche, Google.

Vast program of clinical trials, with 5 successfully completed and 2 in progress.

Commercial launch underway for Diabeo® and Insulia® (therapeutic solutions for diabetes) in Europe and the US.

First payer contract announced with WelldyneRx.

120 employees located in Paris and Boston.

Use of proceeds include the scale-up of commercial activities in North America and Europe and the development of the company’s proprietary multi-cancer solution.

Transaction highlights

Bryan, Garnier & Co acted as Joint Global Coordinator and Joint Bookrunner.

First digital therapeutics IPO globally and first healthcare IPO on Euronext in 2018.

EUR 30.1 million raised in gross proceeds.

IPO anchored by tier-1 leading international healthcare investors including Sanofi Ventures.

Geographically diverse institutional demand with France representing only 18%.

Voluntis' IPO is the 10th healthcare transaction closed by Bryan, Garnier & Co in 2018, following Celyad's successful EUR 46.1 million placement and Medigene's EUR 48.3 million equity offering.

Market cap at IPO: EUR 105.9 million.

About Voluntis

Voluntis creates digital companions that empower people to self-manage their treatment in remote collaboration with their health care teams. Dedicated to chronic conditions, Voluntis’ products aim to personalize treatment, support team-care coordination and improve real-world outcomes. Voluntis leverages its expertise in digitizing clinical algorithms and its technology platform to design its companion solutions. These include Insulia and Diabeo in diabetes as well as eCO and Zemy in oncology. Voluntis has long-standing partnerships with leading life science companies such as Sanofi, Roche and AstraZeneca. It is a founding member of the Digital Therapeutics Alliance.

(www.voluntis.com)

About Bryan, Garnier & Co

Bryan, Garnier & Co is a European, full service growth-focused independent investment banking partnership founded in 1996. The firm provides equity research, sales and trading, private and public capital raising as well as M&A services to growth companies and their investors. It focuses on key growth sectors of the economy including Technology, Media & Telecoms, Healthcare, Smart Industries & Energy, Consumer, Brands & Retail and Business Services. Bryan, Garnier & Co is a fully registered broker dealer authorized and regulated by the FCA in Europe and the FINRA in the U.S. Bryan, Garnier & Co is headquartered in London, with additional offices in Paris, Munich, Zurich and New York. The firm is a member of the London Stock Exchange and Euronext.

(www.bryangarnier.com)

Deal team

Hervé Ronin
Partner
T: +33 1 70 36 57 22

Pierre Lafitte
Director
T: +33 1 56 68 75 08

Romain Ellul
Vice President
T: +33 1 70 36 57 22

Cosme Rosellini
Vice President
T: +33 1 56 68 75 28

Pierre Cuer
Analyst
T: +33 1 56 68 75 47


The Essentials

Everything you need to know about investment banking dedicated to growth
Stay Informed
Get our news
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities